首页 | 本学科首页   官方微博 | 高级检索  
检索        


Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model
Authors:Ayhan Dursun  Mustafa Kemal Arici  Feyza Dursun  Ayse Vural Oze  Mustafa Ilker Toker  Haydar Erdogan and Aysen Topalkara
Institution:Department of Ophthalmology, School of Medicine, Cumhuriyet University, Sivas, Turkey;Department of Ophthalmology, School of Medicine, Cumhuriyet University, Sivas, Turkey;Department of Ophthalmology, School of Medicine, Cumhuriyet University, Sivas, Turkey;Department of Ophthalmology, School of Medicine, Cumhuriyet University, Sivas, Turkey;Department of Ophthalmology, School of Medicine, Cumhuriyet University, Sivas, Turkey;Department of Ophthalmology, School of Medicine, Cumhuriyet University, Sivas, Turkey;Department of Ophthalmology, School of Medicine, Cumhuriyet University, Sivas, Turkey
Abstract:AIM: To investigate the effects of bevacizumab and ranibizumab on corneal neovascularization in an alkali burn-induced model of corneal angiogenesis. METHODS: Fifteen Wistar albino rats were divided randomly into 3 groups after chemical cauterization of the cornea. The first group received a single dose of 0.1mL saline solution as a control group whereas second and third groups received a single dose of 2.5mg bevacizumab or 1mg ranibizumab by subconjunctival injection, respectively. After three weeks, the rat corneas were evaluated by biomicroscopy and corneal photographs were taken. The percentage of neovascularization area, length of the longest new vessel, corneal edema and corneal opacity scores were assessed. RESULTS: The analysis of digital photographs showed that the percentage of neovascularization area to the total corneal area, the length of the longest new vessel, corneal edema and opacity scores were significantly lower in both study groups compared to the control group (P<0.05). Additionally, the percentage of corneal neovascularization area, the length of the longest new vessel and corneal opacity score were less with bevacizumab than ranibizumab. CONCLUSION: Subconjunctival bevacizumab and ranibizumab treatments may be effective methods in reducing corneal neovascularization. Furthermore, bevacizumab is more effective than ranibizumab in the inhibition of corneal neovascularization.
Keywords:corneal neovascularisation  bevacizumab  ranibizumab
本文献已被 PubMed 等数据库收录!
点击此处可从《国际眼科杂志(英文版)》浏览原始摘要信息
点击此处可从《国际眼科杂志(英文版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号